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1. Introduction 
1.1. Gut microbiota, health and diseases  
In humans there are a multitude of site-specific communities of bacteria localized on the 
skin, mucosal surfaces, and in the intestinal tract [1,2]. The total number of prokaryotic cells 
is estimated to be around 1014, ten times more than the number of eukaryotic cells. These 
microbial communities interact extensively with the host, a process which is crucial for host 
development and homeostasis. Most of the microbiota is located in the gastrointestinal (GI) 
tract, and progressively increase in number from the jejunum to the colon. In the colon, the 
levels of bacteria are as high as 1011 microorganisms per gram of luminal content with a very 
wide diversity. The composition of gut microbial communities was originally known 
through culture-based studies, which estimated that 400 to 500 different species are present 
in the adult human intestinal tract [3]. Through the most recent culture-independent 
analyses, gut microbiota is thought to comprise up to 1000 bacterial species per individual 
and over 5000 species in total [4]. The gut microbiota is dominated by only four phyla, i.e. 
Firmicutes, Bacteroidetes, Actinobacteria, and Proteobacteria, although there are more than 
50 bacterial phyla on Earth [1].  
Although the gut microbiota community was mostly studied in terms of pathogenic 
relationships for several decades, it is now recognized that most microorganism-host 
interactions in the gut are, in fact, commensal or even mutualistic [1,2]. This complex 
ecosystem has many functions which contribute to major roles for the host, including 
metabolic functions, barrier effects, and maturation of the immune system [5,6]. Indeed, 
bacterial colonic fermentation of non-digestible dietary residues and endogenous mucus is 
an important metabolic process in humans. The metabolites produced by this bacterial 
fermentation are mostly short-chain fatty acids (SCFAs) which supply energy and nutritive 
products to the bacteria, and trophic functions on the intestinal epithelium [7]. However, 





metabolites, such as phenol, amines, indols, and thiols [8]. The barrier effect refers to a 
resistance to colonization by exogenous or opportunistic bacteria that are at a low level in 
the gut [9]. Many mechanisms are thought to be responsible for this effect, including 
secretion of antimicrobial molecules, competition for nutrients, and attachment to ecological 
niches. These mechanisms also contribute to maintaining equilibrium in the microbial 
population of the gut. Finally, the gut microbial community has a major immune function 
[10].The intestinal immune system is separated from the gut microbiota by a single epithelial 
layer, which allows cross-talk between bacteria and the host. The commensal gut microbiota 
therefore profoundly influences the development of the intestinal adaptative immune 
system, being crucial for the development of gastrointestinal lymphoid tissue (GALT), 
homeostasis between T-helper 1 (Th1) and T-helper 2 (Th2) cell activity , as well as the 
acquisition of oral tolerance [10].  
As the gut microbiota is greatly involved in the intestinal homeostasis, any dysbiosis could 
lead to dysfunctions. Hence, several diseases have been associated with alterations in the 
composition of the gut microbiota such as inflammatory bowel diseases (IBD) [11,12], 
irritable bowel syndrome (IBS) [13], and allergic diseases [14].  
As IBD is concerned, although a direct pathogenic role for a specific agent has not been 
shown, there is evidence that autochthonous intestinal microbiota is involved (for review, 
see [15]). Several studies through culture-dependent and –independent analyses have 
reported differences in microbiota in patients suffering from IBD compared to healthy ones 
with less diversity in fecal microbiota [11] and higher numbers of mucosa-associated 
bacteria [16] in IBD patients. Indeed, IBD patients have fewer bacteria with anti-
inflammatory properties and/or more bacteria with proinflammatory properties [15]. 
Likewise, some clinical studies reported differences in the composition of bacterial 
communities compared to period without allergic symptoms [17,18].  
Irritable bowel syndrome (IBS) is defined by functional recurrent abdominal pain associated 
with abdominal distension and changes in bowel habits (constipation, diarrhea, or both). 
The etiology remains elusive; however, there is growing evidence of the role of gut 
microbiota in IBS [19].  
Some recent studies have also suggested that obese individuals have a higher abundance of 
Firmicutes at the expense of Bacteroidetes in their gut microbiota compared with lean people 
[20,21]. This increase was reversed by surgically-induced or diet-induced weight loss [20,22]. 
Type 2 diabetes seems also to be associated with changes in gut microbial composition, 
regardless of body weight [23,24]. However, such associations have not been found by all 
authors [25]. Differences in the composition of gut microbiota have also been linked with 
type 1 diabetes [26].  
Lastly, antibiotic courses have been shown to impact the microbiota with long term 
alterations [27,28]. Few studies investigated the health consequences of such alterations, but 
for Clostridium difficile colonization, responsible for antibiotic-associated diarrhea or 
pseudomembranous colitis [29].  
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These associations need to be confirmed in large studies. Moreover, it is still unclear 
whether the altered microbiota composition is a consequence rather than a cause of these 
disorders. Moreover, microbiota could promote disease in genetically susceptible hosts. 
Nevertheless, studies conducted to identify relationships between gut microbiota and 
diseases are a prerequisite to new approaches of therapeutics.  
2. Probiotics, prebiotics, tools for modulating the gut microbiota 
The associations of gut microbiota and diseases have given rise to the interest in 
manipulating gut microbiota as a new means of prevention or therapy. Indeed, some 
bacteria, mainly bifidobacteria and lactobacilli, have for a long time been thought to have 
beneficial health effects. They were firstly described by a few visionary scientists like 
Metchnikoff, Nissle, and Shirota about a century ago. This concept of “useful microbes” as 
written by Metchnikoff in his publication “On the prolongation of life” in 1907 [30] has led 
many years later to the use of “probiotic” strains to deliberately manipulate the microbiota. 
This concept has been forgotten during the expansion of the era of antibiotics and vaccines. 
However, research on the roles of the commensal microbiota gave a renewed interest for 
these beneficial microorganisms. Currently, probiotics are defined as “live microorganisms 
which when administered in adequate amounts confer a health benefit on the host” [31,32]. 
The most widely used probiotics include lactic acid bacteria, specifically Lactobacillus and 
Bifidobacterium species [33]. Although the efficacy of probiotics is sometimes debatable, they 
offer great potential benefits to health and are safe for human use, and their areas of interest 
are wide [34]. Effectiveness has been reported in the treatment and/or prevention of various 
gastrointestinal diseases, such as acute viral gastroenteritidis, antibiotic-associated diarrhea, 
pouchitis, and irritable bowel syndrome [33,35,36]. Some beneficial effects have also been 
reported in ulcerative colitis, ventilator-associated pneumonia, functional constipation, and 
reduction of cholesterol (see [34] for review).  
Their beneficial effects could be through the production of metabolites, such as short chain 
fatty acids or other small molecules, or the bacterial components, such as DNA or 
peptidoglycan. However, these effects are strain-specific and further work is still required to 
confirm their benefits to health. 
Modulation of the gut microbiota can be also achieved by the use of prebiotics. Prebiotics 
are defined as non-digestible dietary components that beneficially affects the host by 
selectively stimulating the growth and/or the activity of one or a limited number of bacteria 
in the colon, and thus improves host health [37]. They are mainly oligosaccharides, and 
bacteria mainly enhanced are bifidobacteria. Their potential interest lies in the fact that their 
effect is linked to a modification of the equilibrium of the autochthonous gut microbiota and 
not to a single or a limited number of exogenous strain(s) as for probiotics. Moreover, in 
terms of safety, they have not the side effect of probiotic supplementation, for which 
systemic translocation of the ingested live bacteria has been reported in some cases during 
probiotic uses [38]. Prebiotic supplementation has been less studied than probiotic 





bifidobacteria levels, their effects in terms of health benefits of an early use of infant formula 
enriched with prebiotics appear with limited or unclear clinical significances [39]. Thus, the 
Committee on Nutrition of the European Society for Paediatric Gastroenterology, 
Hepatology, and Nutrition (ESPGHAN) did not recommend the routine use of prebiotic-
supplemented formula [39]. However, no adverse effects have been observed.  
The increase use of association of probiotics and prebiotics, named “synbiotic” is appealing. 
However, a very limited number of such supplementation has been studied in infants. An 
alternative option is the use formulas fermented with lactic acid-producing bacteria during 
the production process that are subsequently inactivated by heat or other means at the end 
of the process [40]. This leads to a probiotic/prebiotic activity likely related to both 
production of active bacterial metabolites such as transoligosaccharides and presence of 
bacterial components such as cell membrane and DNA [41,42]. The limited number of 
studies on this kind of formula does not allow general conclusions to be drawn on the use 
and effects of fermented formulae [40]. It is recommended that the observed effects should 
be assessed in further randomized controlled trials.  
Both uses of prebiotics and synbiotics in neonates are not included in the present review.  
3. Gut bacterial establishment 
The formation of the intestinal ecosystem starts rapidly during the neonatal stage of life (see 
[43,44] for review). Colonizing bacteria originate mainly from the mother; the gut microbiota 
is a major source. Other sources include the microbiota of the vagina, perineum, skin, and 
even breast milk [45,46]. The first colonizing bacteria are facultative anaerobes due to the 
abundance of oxygen in the gut. This decreases the redox potential in the gut lumen, 
creating a reduced environment that favors the establishment of obligate anaerobes [43]. 
However, little is known about the factors that lead to the establishment of specific bacterial 
strains. Then, during the infant stage of life, numerous bacteria are encountered in the 
environment including the skin microbiota of parents, siblings, nurses, and foods. Hence, 
over time, successively larger numbers of bacteria are established in the infant gut, and 
these are mainly comprised of obligate anaerobes. This leads to a high interindividual 
variability in the composition and patterns of bacterial colonization during the first weeks of 
life. By the end of the first year of life, the gut bacterial composition converges toward an 
adult-like microbiota profile [47].  
Various external factors can affect the pattern of bacterial colonization, i.e. mode of delivery, 
mode of infant feeding, and environment [43,44]. Infants born by cesarean section are 
deprived of contact with their mother’s gut and vaginal microbiota, which decreases 
bacterial diversity and colonization by obligate anaerobes such as bifidobacteria and 
Bacteroides [48,49]. The mode of infant feeding also strongly influences bacterial 
establishment, the hallmark being a dominant colonization by bifidobacteria in breastfed 
infants compared with formula-fed ones. However, improvements in infant formulas have 
led to only minor differences in colonization following each feeding method [43,44]. 
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Moreover, changes in the establishment of gut microbiota have been observed in modern 
Western infants, most likely due to improved hygiene and general cleanliness in Western 
countries, resulting in reduced bacterial exposure [43,44]. Finally, gestational age can also 
affect bacterial colonization. Preterm birth leads to a delayed and abnormal pattern of 
microbial colonization in the gut [50-53]. In particular, colonization by beneficial bacteria 
such as bifidobacteria, which are normally dominant in fullterm babies, is delayed especially 
in very and extremely preterm neonates [54].  
4. Gut microbiota and pediatric diseases: a rational for probiotic use in 
neonates  
The early bacterial pattern in the first weeks of life appears to be a crucial step in the 
establishment of the various functions of the gut microbiota. In fact, recognition of self– and 
non–self–antigens begins early in life, perhaps even in utero [55]. Maturation of the intestinal 
immune system is thought to be significantly affected by the sequential bacterial 
establishment [10,56]. Indeed, at birth, the lymphoid system is not yet mature even though it 
is developed and the fetus is in a Th2 immunological context, and Th1 responses are 
repressed in order to avoid its rejection [57]. Therefore, after birth, the newborn must 
quickly restore the Th1/Th2 balance. The existence of a rich microbial environment is 
thought to be important in this process, the first bacteria to colonize the infant’s gut being 
the first stimuli for post-natal maturation of the T-helper balance. The immature Th2-
dominant neonatal response undergoes environment-driven maturation via microbial 
contact during the early postnatal period resulting in a gradual inhibition of the Th2 
response and an increase of the Th1 response and prevention of allergic diseases which are 
Th2 linked, a basis of the so-called “hygiene hypothesis” [56].  
Late-onset diseases could be therefore associated with an impairment of this step, all the 
more as early impairment in bacterial establishment can have long term effects in terms of 
bacterial pattern [58] as well as in terms of immune maturation [49,59]. Indeed, a large 
number of studies have shown that an imbalance of the numbers of Th1 and Th2 cells may 
be at the origin of a great variety of disease processes.  
The first disease associated to this imbalance is allergy. Thus, the initial composition of the 
infant gut microbiota may be a key determinant in the development of atopic disease [60]. 
This hypothesis is consistent with the delayed colonization of the digestive tract associated 
with changes in lifestyle over the last 15 years in Western countries [43,44], where incidence 
of allergic diseases had sharply increased since a decade. Moreover, factors known to 
modify establishment of the gut microbiota, e.g. birth through caesarian section [61,62], 
prematurity [63], and exposure to antibiotics during pregnancy [64] have been associated 
with a higher risk of atopic disease. This hygiene hypothesis implicating a relationship 
between allergic diseases and gut microbiota is supported by several clinical studies which 
reported differences in the composition of the fecal microbiota between infants who live in 





allergic diseases. In fact, several reports have associated allergic diseases with abnormal 
bacterial pattern. Low diversity [65] and low levels of bifidobacteria have been associated 
with allergy development [66,67], as well as high levels of clostridia [14,66]. A recent study 
revealed differences in the abundance of Bifidobacterium and enterobacteria among 7 
cesarean-delivered infants with and without eczema over a 2 year-follow-up and preceding 
the apparition of the symptoms [68].  
Likewise, early alterations in the gut microbiota have been linked with the risk of later 
overweight or obesity associated with lower levels of bifidobacteria and higher levels of 
Staphylocccus aureus during the first year of life [69].  
For many years, a number of studies have documented differences between patients 
suffering from inflammatory bowel diseases and healthy persons, even if there is still debate 
about whether changes precede or follow the development of IBD [70]. For instance, a 
decreased prevalence of dominant members of the human commensal microbiota, i.e. 
Clostridium IXa and IV groups, Bacteroides, bifidobacteria and a concomitant increase in 
detrimental bacteria, i.e. sulphate-reducing bacteria and Escherichia coli has been reported 
[71]. A pilot study found differences in mucosa-associated bacteria in duodenal mucosa 
with higher number of aerobic and facultative-anaerobic bacteria and a decrease in 
Bacteroides, a strictly anaerobic genus in pediatric IBD patients compared to control patients 
[72]. This peculiar microbial profile, with higher diversity in duodenal mucosa from 
children suffering from celiac disease and the specific harmful role of Escherichia coli 
supported the idea of a disease associated with the gut microbiota environment [73,74]. 
Other studies reported decrease in fecal and duodenal bifidobacteria populations in celiac 
patients [75]. 
Lastly, associations between intestinal microbiota and autism have been reported such as 
the overgrowth of neurotoxin-producing clostridia [76]. Several reports indicate that certain 
clusters of clostridia are present in higher levels in fecal microbiota from autistic infants 
[77,78]. Overgrowth of Desulfovibrio sp may also lead to direct damage through interaction 
between the host and lipopolysaccharide and sulfate reduction [79].  
Hence, although a causal relationship has not been categorically established, there is 
emerging evidence that the initial gut bacterial colonization during the first weeks of life is 
of great importance for infant health. Perinatal determinants altering the colonization 
pattern could therefore lead to a higher risk of later diseases. For instance, as already 
mentioned, infants born through cesarean section and therefore colonized by an altered 
bacterial pattern as compared with vaginally delivered ones have been reported to be at 
higher risk of either allergic diseases [80-82], or celiac disease [83], or obesity [84-86], or type 
1 diabetes [87]. A prolonged breast-feeding over one year has been linked to a lower risk of 
overweight or obesity [88]. Likewise, changes in the establishment of gut microbiota 
observed in modern Western infants result in reduced bacterial exposure [43,44]. Thus, these 
infants lack of adequate bacterial stimuli, leading to a deviated maturation of their immune 
system likely responsible for a higher risk of allergic disease development or inflammatory 
bowel diseases [56].  
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5. Probiotics in fullterm neonates  
The potential benefits of the use of probiotics in pediatrics have been recently reviewed 
[89,90]. It mainly includes treatment acute viral gastroenteritis [91], prevention of antibiotic-
associated diarrhea [92,93], reduction of the inflammatory response in IBD patients [11]. 
Limited effects have been observed in colicky infants [94]. However, a recent study reported 
a clear improvement of the symptoms of colic within one week of Lactobacillus reuteri 
administration as compared with simethicone treated infants [95] linked to an antimicrobial 
effect against six species of gas-forming coliforms isolated from the colicky infants [96].  
Given the likely link between the early bacterial pattern and later health status reported, a 
very early administration of probiotics when the gut microbiota is not fully established is of 
great interest and we have focused this review on this approach. Many attempts of early 
probiotic supplementation have been made for a long time, and numerous studies related to 
the use of infant formula supplemented with probiotics strains have been recently published 
[39]. This early use is reported to have some beneficial effects in terms of prevention of late 
development of some diseases. Administration is often given soon after birth, and the 
duration is variable according to the study, but often prolonged over several weeks or 
months. Lastly, dosages varied, ranging from 106 to ~109 CFU/mL or/g. The most frequently 
studied probiotic strains were Bifidobacterium animalis subsp lactis, B longum, Lactobacillus 
rhamnosus, L reuteri, L johnsonii and Streptococcus thermophilus, used alone or in combination.  
Some studies have included the effects of such supplementation on growth. However, no 
significant effects have been shown on growth, but without any negative results [39]. 
Likewise, no reduction of gastrointestinal or respiratory infections, or reduction of antibiotic 
use have been reported, but a limited number of studies investigated such effect, avoiding to 
drawn final conclusions. Moreover, one difficulty to assess the health-promoting effects lies 
in the fact that the probiotics properties are strain-dependent and the use of different strains 
could explain the discrepancies between the observed effects. Second, mechanism(s) of 
action of the probiotics is not always well-established. Probiotics can have health-promoting 
effects related to their interaction with the gut microbiota, the barrier functions and the 
immune system. In particular, probiotic supplementations were shown to impact the 
intestinal maturation as reported with Bifidobacterium lactis supplementation of preterm 
infants which induced the maturation of the intestinal IgAs response [97]. Likewise, in 
fullterm neonates an infant formula containing two strains of probiotics allowed the 
preservation of high SIgA levels at 6 months compared to the control group [98]. 
Furthermore, such supplementation was suggested to have a synergistic effect on gut 
humoral immunity at 12 months of age, since it has shown that significant higher level of 
total IgM, IgA, and IgG titers was detected in infants who had been breastfed exclusively for 
at least 3 months and supplemented with probiotics compared with those breastfed 
receiving placebo [99]. Probiotic strains can also improve the intestinal barrier functions by 
inducing mucin production. Besides, they can interact directly with intestinal bacteria 






The prevention of allergy through such early administration of probiotics is appealing. 
Though evidence of their effect is conflicting, their administration to infants at high risk for 
atopy and/or to their mothers seems to be effective for preventing infants from developing 
atopic disease [101,102]. Four studies investigated probiotic supplementation begun during 
pregnancy. Administration of Lactobacillus GG to the mother during pregnancy and breast-
feeding appears to be a safe and effective method for enhancing the immunoprotective 
potential of breast milk and preventing atopic eczema in the infant [103,104], with a 
protective effect up to 7 years [105]. However, this preventive effect was not confirmed in a 
similar study by Kopp et al, may be due to differences in the study populations [106]. L 
reuteri supplementation in infants with a family history of allergic disease did not confirm a 
preventive effect against infant eczema but found a decreased prevalence of IgE-associated 
eczema during the second year [107]. Infants receiving L rhamnosus had a significantly lower 
risk of eczema than infants receiving placebo, but this was not the case for B animalis subsp 
lactis and there was no significant effect of these two strains on atopy [108]. Other trials 
consisting of supplementation with various probiotics strains only in infants from birth to 6 
months of life did not find any reduction of the risk of atopic disease in high-risk infants 
[109-111]. Discrepancies between the observed effects could be linked to the various 
probiotics strains used. Indeed, the mechanism of their action could be through the 
maturation of the immune system, as suggested by the study of Roze et al where low levels 
of IgAs in the control group has been associated with atopy [98].  
These data led the Nutrition Committee of ESPGHAN to conclude that there is too much 
uncertainty to draw reliable conclusions [39], confirmed through a recent review [112]. 
However, the Cochrane Database of Systematic Reviews claimed that there is a possible role 
a probiotics intervention in prevention of atopic dermatitis [113]. These promising results 
associated to the fact that the impact on the immune system has been shown to be strain-
dependant [114] highlighting the importance of the choice of the probiotic strain argue for 
further studies in this field.  
Identifying through animal studies and clinical studies a possible link between gut 
microbiota and obesity [69,84,86] may offer promising strategies through the gut 
modulation to prevent obesity. The intestinal microbiota may contribute to the development 
of inflammation and insulin resistance leading to overweight or obesity, either by its role in 
the regulation of energy homeostasis and fat storage or by the chronic inflammation it could 
induce, or both [21,115]. Reducing the susceptibility to obesity by early probiotics 
intervention would be a useful adjunct in strategies to alleviate the huge burden of 
childhood obesity which can be a risk factor for later diseases such as type 2 diabetes, 
hypertension and coronary heart disease [116]. The findings of early differences in 
microbiota of infants who later become overweight or obese [69] argues for an early 
intervention. Likewise, differences in obese and non obese children has been found [117,118]  
Up to now, only one study on the effects on obesity of early probiotics supplementation has 
been conducted [119]. Pregnant women (n=159) were randomized and double-blinded to 
receive L rhamnosus or placebo 4 weeks before expected delivery; the intervention extending 
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for 6 months postnatally. Anthropometric measurements were taken over 10 years. This 
perinatal probiotic administration appeared to moderate the initial phase of excessive 
weight gain, especially among children who later became overweight, but not the second 
phase of excessive weight gain, the impact being most pronounced at the age of 4 years. The 
effect of intervention was also shown as a tendency to reduce the birth-weight-adjusted 
mean body mass index at the age of 4 years. Another controlled trial has been performed 
but on children between 12 and 15 of age over a 12-week period [120]. The probiotics used 
was L salivarius and the objective was to investigate the effect of the probiotics 
supplementation on markers of inflammation and metabolic syndrome, showing no 
beneficial effects on these markers. This may be highlights again the usefulness of an early 
intervention before the onset of the clinical and/or biological signs.  
6. Probiotics in preterm neonates  
6.1. Gut bacterial establishment in preterm neonates 
The current more obvious interest of probiotics use in neonates is very likely for preterm 
infants. In fact, preterm infants, and particularly those who are born at a low or very low 
gestational age and/or birth weight experience a delayed and abnormal pattern of gut 
colonization, particularly with regard to bifidobacteria and lactobacilli, normally dominant 
in healthy full term infants. The first studies on the gut bacterial colonization in preterm 
infants, based on culture methods and performed in the 80s, described a delayed 
colonization by many of the bacteria found in healthy fullterm infants [121-123]. However, 
more recent studies reported a greater delay either by culture [124-126] or culture-
independent methods [50,124,126-130]. Recently, the use of a pyrosequencing-based method 
confirmed this aberrant pattern in low and very low birth weight infants [52].  
The predominant facultative bacterial species in the fecal microbiota of preterm infants 
undergoing intensive care are staphylococci. Enterobacteria (mainly Klebsiella sp and 
Enterobacter sp) and enterococci are slightly delayed. Clostridia are the most common 
anaerobes during the first weeks of life, often the dominant anaerobic microbiota 
[124,126,131]. In contrast, Bacteroides and in particular bifidobacteria – known for their 
potential beneficial effects – seldom colonize preterm infants by contrast with fullterm 
infants [50,54,124]. Moreover, gestational age appears a major factor influencing their 
establishment [50,54]. Finally, the hospital environment can influence the bacterial pattern 
[131].  
This bacterial establishment is the expression of colonization from the environment rather 
from maternal origin. A combination of more frequent birth through cesarean section, large 
antibiotic use, delayed initiation of enteral feedings, and exposure to the unusual 
microorganisms that populate the neonatal intensive care units may explain this abnormal 
pattern of colonization.  
This impaired intestinal colonization may predispose preterm infants to diseases. Indeed, 





Both the permanent exposure to microorganisms due to frequent invasive procedures and 
the immaturity of the newborn immune system are responsible for the increased 
susceptibility to severe nosocomial infections. Early-onset sepsis remain an important cause 
among very preterm infants [132], thought to be due – at least partly – to the gut microbiota, 
Gram negative bacilli being the most frequent bacteria encountered in sepsis by contrast 
with fullterm infants [132]. Recent studies have demonstrated the origin of gut bacteria in 
these infections [133,134]. Besides, necrotizing enterocolitis (NEC) remains an important 
cause of morbidity and mortality among very preterm infants. Despite many investigations, 
its pathogenesis remains unclear [135]. The hypothesis that intestinal microbes are necessary 
for the development of NEC is supported by several lines of evidence [136]. No specific 
bacteria or bacterial pattern has been causally associated with the development of NEC 
although bacterial colonization is recognized as an important factor [137-139]. Implication of 
bacteria is thought to be due to fermentation of non-hydrolyzed lactose, a consequence of 
the immaturity of the intestinal lactasic equipment in preterm infants [140-142]. The genus 
Clostridium seems to be important in the pathogenesis of NEC [139,143,144], but other 
genera could be involved [51,130,145]. A decrease in microbial diversity [130] or an increase 
in enterococci and Citrobacter gene sequences in NEC infants has been observed [51]. 
Lastly, the very abnormal pattern observed particularly in VLBW infants could lead to an 
abnormal maturation of the functions of the intestinal ecosystem. Indeed, it could be a factor 
to develop late-onset disease such as allergy, obesity, such as suggested with a higher risk of 
allergy in infants born with a very low birth weight (VLBW)[63].  
6.2. Probiotics in preterm neonates 
Feeding oral probiotic bacteria may be therefore an effective way to change the abnormal 
pattern of colonization of preterm infants, and to have the potential to prevent the 
occurrence of gastrointestinal disorders in preterm infants. A relatively small number of 
trials have studied the effects of probiotics in those preterm infants. However, numerous 
meta-analyses or reviews (with a higher number than clinical trials, highlighting the great 
interest in this approach) have shown the potential benefits of such supplementation, 
leading to a significant and somewhat impressive reduction of all-cause mortality and NEC 
by more than half [146-148]. As for an example, the metaanalyse from the Cochrane 
Collaboration included 16 studies with 1371 infants treated with probiotics and 1376 controls 
[146]. Various probiotic strains have been used, i.e. lactobacilli, bifidobacteria or a combination 
of 2 or 3 strains. The most frequent Lactobacillus used was LGG. For bifidobacteria, breve and 
longum were the most frequent species administered. One study used Saccharomyces boulardii. 
Conclusions of this metaanalyse are concordant with other ones, with a significant decrease in 
the incidence of severe NEC (stage II or more) and of mortality. As highlighted for other 
applications, the effect is certainly strain-dependent with studies that did not found any 
beneficial supplementation regarding the incidence of NEC [149]. 
Other beneficial effects have been reported as a shortened time to full feeds. By contrast, if 
there is a trend toward a reduction of nosocomial sepsis, it does not reach the significance.  
 
Usefulness of Probiotics for Neonates? 
 
467 
These beneficial effects are less obvious in extremely preterm infants, born with a very low 
birthweight (1000g or less, VLBW infants) [146]. This could be related with the fact that the 
probability to be colonized by probiotic strains diminished with decreasing birth weight 
[126]. Hence, in this latter study the improvement of gastrointestinal tolerance to enteral 
feeding was only reported in infants born with a birthweight >1000g. As infants weighting 
1000g or less received antibiotic treatment more frequently, and had more frequent 
interruptions of enteral feeding than did infants weighing more than 1,000g, these findings 
suggest that these factors could prevent gut colonization by the probiotic strains, and, 
consequently, the capacity of probiotics to enhance intestinal function in extremely low birth 
weight infants [126].  
Conclusions of the numerous reviews and metaanalyses strongly suggest that the use of 
probiotics in preterm infants could prevent tens of thousands of deaths annually. Hence, 
some authors recommend that it is time to change practice and to adopt the use of 
probiotics as a standard care in preterm infants [146,150]. However, controversies have 
emerged because there are yet too many unknowns about probiotics use [151,152]. One 
aspect concerns the safety although no negative effects have been reported even in long 
term follow-up [153]. However, data on this latter aspect are very scarce. Infrequent, 
systemic translocation of probiotics has been reported [38,154] raising some concerns 
about this side effect in the high-risk groups of low and very low birth weight infants who 
are characterized by high intestinal permeability, making this potential powerful tool a 
double-edge weapon. Increased incidence of NEC following probiotic administration has 
been observed in a preterm piglet model, may be related to the specific strain, dose, and 
the very immature gut immune system.[155]. A study in a pediatric unit even reported a 
trend toward an increase in nosocomial throughout a probiotic supplementation [156] 
although a routinary supplementation of VLBW infants with a probiotics strains over a 6-
year period was safe [157].  
To conclude, although there is encouraging data for the use of probiotics in particular in 
terms of NEC prevention, it may be reasonable to stand back from a routine use of 
probiotics in preterm infants. As suggested by several authors, probiotics 
supplementation should be a local decision [158-161]. Several questions have been raised. 
What is the interest of probiotic supplementation in units with low incidence of NEC? 
What are the mechanisms of action, which are not elucidated, in particular due to the lack 
of gut microbiota analyses in most of the studies? What are the beneficial effects apart 
reduction of incidence and severity of NEC, in particular concerning sepsis, since some 
results are promising, but large clinical trials are needed, as the ongoing study in 
Australia and New Zealand [162]. What is the safety of the various strains? Which 
product(s) should be administered, at what dose, when, and for how long [163]? Lastly, 
no general recommendation can be done currently for the special group of the VLBW 
infants regarding the lack of benefits of probiotics supplementation [146,160]. Further 





Lastly, no study had investigated the potential beneficial long-term effect of an early 
probiotics supplementation in terms of reduction of the risk of late-onset disease linked to 
an early dysbiosis such allergy and obesity for instance.  
The Committee on Nutrition of ESPGHAN concluded – in a commentary published in 2010 
– that there is not enough available evidence for a routine use of probiotics in preterm 
infants [164]. However, faced to some evidence of benefits of probiotics in preterm infants, 
guidelines have been proposed aiming at optimizing their use, emphasing that “routine” 
use does not equate “blind” use of probiotics, and raising the necessity to continue research 
in this field to provide answers to the current gaps [159].  
7. Conclusion  
The notion of “gut health” has become more and more popular. Currently, it is recognized 
that the gut microbiota contributes to the host health not only by assuming digestion and 
absorption of nutriments, but also by maturation of the immune system, defense against 
infection, signaling to the brain… 
This leads to not only study the gut microbiota communities in terms of pathogenic 
relationships, as it was done for several decades, but also to study the endogenous microbiota 
and to investigate microorganism-host interactions in the gut that are, in fact, commensal or 
even mutualistic. Hence, currently several disease, which clinical symptom can be late in the 
life, are linked to dysbiosis that often occurred in the early step of gut colonization.  
We need to learn more about the composition and functions of the gut microbiota and to the 
concept of early modulation of this microbiota. Thus, we are currently at the beginning of 
the era of probiotics which aim at counteracting deleterious effect of microorganisms with 
probiotics instead of using vaccines and antibiotics. This new field of medical microbiology 
is appealing and fascinating.  
The current review aimed at giving the rational of the use of probiotics for promotion of 
health and prevention of disease through their use early in life when the gut microbiota is 
not fully established.  
Several applications are claimed among them, some are appealing such as prevention of 
allergy. However, up to now, there are not enough data to recommend their routine use. But 
the potential interest in this field argues to do further research to validate the current 
beneficial results observed.  
The most clear potential interest of early probiotic supplementation lies in taking care of 
preterm neonates, who are often colonized by an aberrant microbiota leading to high risks 
of early or late-onset of disease. Probiotic supplementation has been demonstrated to have 
benefits in terms of prevention of NEC. However, too many questions remain unanswered 
to recommend their routine use. One major concern is the safety linked to the ingestion of 
live microorganisms by an immature host. Hence, once again further research is needed in 
this exiting field with potential of health benefits.  
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